(Q39212192)

English

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling

scientific article published on 15 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

The proteasome inhibitor bortezomib stimulates osteoblastic differentiation of human osteoblast precursors via upregulation of vitamin D receptor signalling (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

0 references

0 references

author name string

Martin F Kaiser

1

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Ulrike Heider

2

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Maren Mieth

3

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Chuanbing Zang

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Ivana von Metzler

5

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Orhan Sezer

6

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

publication date

15 February 2013

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

European Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

90

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

263-272

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Myeloma and the newly diagnosed patient: a focus on treatment and management

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Pathophysiology of multiple myeloma bone disease

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Myeloma bone disease: recent advances in biology, diagnosis, and treatment

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Novel aspects of osteoclast activation and osteoblast inhibition in myeloma bone disease

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Bisphosphonates as antimyeloma drugs

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Biochemical, histomorphometric and densitometric changes in patients with multiple myeloma: effects of glucocorticoid therapy and disease activity.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Bortezomib inhibits human osteoclastogenesis.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Bone markers in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Therapy with bortezomib plus dexamethasone induces osteoblast activation in responsive patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Stimulation of new bone formation by the proteasome inhibitor, bortezomib: implications for myeloma bone disease

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Osteoblasts promote migration and invasion of myeloma cells through upregulation of matrix metalloproteinases, urokinase plasminogen activator, hepatocyte growth factor and activation of p38 MAPK.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Impaired gastric acidification negatively affects calcium homeostasis and bone mass.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Osteo-transcriptomics of human mesenchymal stem cells: accelerated gene expression and osteoblast differentiation induced by vitamin D reveals c-MYC as an enhancer of BMP2-induced osteogenesis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Evidence that both 1alpha,25-dihydroxyvitamin D3 and 24-hydroxylated D3 enhance human osteoblast differentiation and mineralization

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Vitamin D action : Lessons learned from genetic mouse models

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

The direct role of vitamin D on bone homeostasis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

First-line treatment with bortezomib rapidly stimulates both osteoblast activity and bone matrix deposition in patients with multiple myeloma, and stimulates osteoblast proliferation and differentiation in vitro

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Increased bone mineral density in a subset of patients with relapsed multiple myeloma who received the combination of bortezomib, dexamethasone and zoledronic acid

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

A prospective evaluation of the biochemical, metabolic, hormonal and structural bone changes associated with bortezomib response in multiple myeloma patients

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Bortezomib induces osteoblast differentiation via Wnt-independent activation of beta-catenin/TCF signaling

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

The importance of nuclear import in protection of the vitamin D receptor from polyubiquitination and proteasome-mediated degradation

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Vitamin D status may effect the skeletal complications of multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12069

21 January 2018

Identifiers

10.1111/EJH.12069

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39212192&oldid=1813142586"